Yu Sato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yu Sato has a total of 121 co-authors. Here are the top co-authors by number of shared publications:
- Akiomi Yoshihisa
Department of Cardiovascular Medicine, Fukushima Medical University
24 shared publications Atsushi Kobayashi
Department of Cardiovascular Medicine, Fukushima Medical University , 1 Hikarigaoka, Fukushima 960-1295
16 shared publicationsMasayoshi Oikawa
Department of Cardiovascular Medicine Fukushima Medical University School of Medicine Fukushima Japan
16 shared publicationsYasuchika Takeishi
Department of Cardiovascular Medicine, Fukushima Medical University , 1 Hikarigaoka, Fukushima 960-1295
16 shared publicationsTakamasa Sato
Department of Cardiovascular Medicine, Fukushima Medical University , 1 Hikarigaoka, Fukushima 960-1295
11 shared publications- Tomofumi Misaka
Department of Cardiovascular Medicine, Fukushima Medical University, Fukushima, Japan
10 shared publications
Latest Publications
- 16 April 2026
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 15 (9) , 660-670
Clinical impact of seasonal and environmental factors in patients with acute heart failure
Aims: Seasonal factors, particularly during winter, have been associated with worsened heart failure (HF). However, seasonal differences in clinical characteristics, clinical outcomes, and environmental mechanisms remain unclear. Methods and results: We analysed 2857 patients hospitalized for HF. Patients were classified into four groups by season of admission: spring (March to May, n = 788, 27.6%), summer (June to August, n = 699, 24.5%), fall (September to November, n = 645, 22.6%), and winter (December to February, n = 725, 25.4%). Baseline characteristics, clinical outcomes, and environmental factors corresponding to the admission month—such as temperature, atmospheric pressure, relative humidity, sunshine duration, influenza activity, and PM2.5 concentration—were compared among the groups. The winter group was older and more frequently had hypertension, diabetes, chronic kidney disease, and thyroid disease. No seasonal differences were observed in sex, body mass index, HF aetiology, other comorbidities, B-type natriuretic peptide levels, or left ventricular ejection fraction. Compared with the fall group, the winter group was associated with higher risk of in-hospital cardiac and all-cause, 90-day cardiac, and all-cause mortality (odds ratio 2.13, 1.85, 1.69, 2.01, 1.80, respectively, P < 0.05). With respect to environmental factors, (i) lower temperature was associated with 90-day cardiac and all-cause mortality; (ii) shorter sunshine duration was associated with 90-day all-cause mortality; and (iii) higher PM2.5 concentrations were associated with in-hospital cardiac mortality. In contrast, atmospheric pressure, relative humidity, and influenza activity were not associated with clinical outcomes. Conclusion: Winter admission for HF was associated with older age, more comorbidities, and higher in-hospital and short-term mortality, which may be partly explained by lower temperatures and shorter sunlight.
- 16 April 2026
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 15 (9) , 660-670
Clinical impact of seasonal and environmental factors in patients with acute heart failure
Aims: Seasonal factors, particularly during winter, have been associated with worsened heart failure (HF). However, seasonal differences in clinical characteristics, clinical outcomes, and environmental mechanisms remain unclear. Methods and results: We analysed 2857 patients hospitalized for HF. Patients were classified into four groups by season of admission: spring (March to May, n = 788, 27.6%), summer (June to August, n = 699, 24.5%), fall (September to November, n = 645, 22.6%), and winter (December to February, n = 725, 25.4%). Baseline characteristics, clinical outcomes, and environmental factors corresponding to the admission month—such as temperature, atmospheric pressure, relative humidity, sunshine duration, influenza activity, and PM2.5 concentration—were compared among the groups. The winter group was older and more frequently had hypertension, diabetes, chronic kidney disease, and thyroid disease. No seasonal differences were observed in sex, body mass index, HF aetiology, other comorbidities, B-type natriuretic peptide levels, or left ventricular ejection fraction. Compared with the fall group, the winter group was associated with higher risk of in-hospital cardiac and all-cause, 90-day cardiac, and all-cause mortality (odds ratio 2.13, 1.85, 1.69, 2.01, 1.80, respectively, P < 0.05). With respect to environmental factors, (i) lower temperature was associated with 90-day cardiac and all-cause mortality; (ii) shorter sunshine duration was associated with 90-day all-cause mortality; and (iii) higher PM2.5 concentrations were associated with in-hospital cardiac mortality. In contrast, atmospheric pressure, relative humidity, and influenza activity were not associated with clinical outcomes. Conclusion: Winter admission for HF was associated with older age, more comorbidities, and higher in-hospital and short-term mortality, which may be partly explained by lower temperatures and shorter sunlight.
- Open Access
- 5 August 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (15) , e039917
Nighttime Systolic Blood Pressure Determined by Pulse Transit Time Predicts Cardiac Events in Patients With Heart Failure
Background: The optimal systolic blood pressure (SBP) target for heart failure (HF) patients has not been established. Although the association between daytime SBP and prognosis has been reported in patients with HF, the prognostic impact of nighttime SBP remains unclear. Methods: We conducted continuous nighttime SBP measurements noninvasively using pulse transit time in 366 patients with HF (median age, 72 years; male sex, 195), and followed up for cardiac events (HF hospitalization or cardiac death). Average values of nighttime pulse transit time –based SBP were used in the present study. The patients were divided into tertile groups based on nighttime pulse transit time–based SBP: high‐SBP group (median SBP, 136 mm Hg; n=122), middle‐SBP group (median SBP, 117 mm Hg; n=122), and low‐SBP group (median SBP, 100 mm Hg; n=122). Results: During a median follow‐up period of 1083 days after nighttime pulse transit time–based SBP measurement, 71 patients experienced a cardiac event. Kaplan–Meier analysis showed the highest incidence of cardiac events in the low‐SBP group. Multivariate Cox proportional hazard analysis also showed that the lowest SBP tertile was associated with a higher risk of cardiac events compared with the highest SBP tertile as reference (hazard ratio, 2.100 [95% CI, 1.121–3.933]; P =0.021). Conclusions: Low nighttime SBP was associated with an increased cardiac event rate in patients with HF.
- 5 August 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (15) , e039917
Open AccessNighttime Systolic Blood Pressure Determined by Pulse Transit Time Predicts Cardiac Events in Patients With Heart Failure
Background: The optimal systolic blood pressure (SBP) target for heart failure (HF) patients has not been established. Although the association between daytime SBP and prognosis has been reported in patients with HF, the prognostic impact of nighttime SBP remains unclear. Methods: We conducted continuous nighttime SBP measurements noninvasively using pulse transit time in 366 patients with HF (median age, 72 years; male sex, 195), and followed up for cardiac events (HF hospitalization or cardiac death). Average values of nighttime pulse transit time –based SBP were used in the present study. The patients were divided into tertile groups based on nighttime pulse transit time–based SBP: high‐SBP group (median SBP, 136 mm Hg; n=122), middle‐SBP group (median SBP, 117 mm Hg; n=122), and low‐SBP group (median SBP, 100 mm Hg; n=122). Results: During a median follow‐up period of 1083 days after nighttime pulse transit time–based SBP measurement, 71 patients experienced a cardiac event. Kaplan–Meier analysis showed the highest incidence of cardiac events in the low‐SBP group. Multivariate Cox proportional hazard analysis also showed that the lowest SBP tertile was associated with a higher risk of cardiac events compared with the highest SBP tertile as reference (hazard ratio, 2.100 [95% CI, 1.121–3.933]; P =0.021). Conclusions: Low nighttime SBP was associated with an increased cardiac event rate in patients with HF.
- Open Access
- 3 September 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (17) , e035139
Reduced Fetuin‐A Levels Are Associated With Exercise Intolerance and Predict the Risk of Adverse Outcomes in Patients With Heart Failure: The Role of Cardiac–Hepatic–Peripheral Interaction
Background: Exercise intolerance in heart failure arises from multifactorial pathophysiological mechanisms. Hepatokines, liver‐synthesized molecules, regulate systemic metabolisms in peripheral tissues. We previously identified the hepatokine fetuin‐A as being linked to liver hypoperfusion in heart failure. Here, we investigated the role of fetuin‐A in connecting cardiac–hepatic–peripheral interaction. Methods and Results: We conducted a prospective study involving 202 consecutive hospitalized patients (mean age, 56.8 years; 76.2% men) with heart failure who underwent cardiopulmonary exercise testing. We measured the serum concentration of fetuin‐A by ELISA. Correlation analysis revealed a negative association between fetuin‐A levels and the ratio of minimum minute ventilation to carbon dioxide production, its slope, and a tendency toward a positive correlation with peak oxygen uptake. Patients with impaired exercise tolerance exhibited lower fetuin‐A levels. During a median follow‐up of 1045 days, 18.3% experienced cardiac events, including 4 cardiac deaths and 33 cases of worsening heart failure. Classification and regression tree analysis identified a high‐risk subgroup with lower fetuin‐A (<24.3 mg/L) and impaired exercise tolerance (peak oxygen uptake<14.2 mL/kg per min). Kaplan–Meier analysis revealed that this subgroup had the highest risk of cardiac events. In a multivariable Cox proportional hazard model, the combination of lower fetuin‐A and exercise intolerance was independently associated with increased risks of cardiac events. Conclusions: Reduced circulating fetuin‐A levels were associated with exercise intolerance in heart failure patients. Fetuin‐A could emerge as a target implicated in exercise capacity connecting cardiac–hepatic–peripheral interaction and as a valuable biomarker for predicting prognosis when combined with peak oxygen uptake.
- 3 September 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (17) , e035139
Open AccessReduced Fetuin‐A Levels Are Associated With Exercise Intolerance and Predict the Risk of Adverse Outcomes in Patients With Heart Failure: The Role of Cardiac–Hepatic–Peripheral Interaction
Background: Exercise intolerance in heart failure arises from multifactorial pathophysiological mechanisms. Hepatokines, liver‐synthesized molecules, regulate systemic metabolisms in peripheral tissues. We previously identified the hepatokine fetuin‐A as being linked to liver hypoperfusion in heart failure. Here, we investigated the role of fetuin‐A in connecting cardiac–hepatic–peripheral interaction. Methods and Results: We conducted a prospective study involving 202 consecutive hospitalized patients (mean age, 56.8 years; 76.2% men) with heart failure who underwent cardiopulmonary exercise testing. We measured the serum concentration of fetuin‐A by ELISA. Correlation analysis revealed a negative association between fetuin‐A levels and the ratio of minimum minute ventilation to carbon dioxide production, its slope, and a tendency toward a positive correlation with peak oxygen uptake. Patients with impaired exercise tolerance exhibited lower fetuin‐A levels. During a median follow‐up of 1045 days, 18.3% experienced cardiac events, including 4 cardiac deaths and 33 cases of worsening heart failure. Classification and regression tree analysis identified a high‐risk subgroup with lower fetuin‐A (<24.3 mg/L) and impaired exercise tolerance (peak oxygen uptake<14.2 mL/kg per min). Kaplan–Meier analysis revealed that this subgroup had the highest risk of cardiac events. In a multivariable Cox proportional hazard model, the combination of lower fetuin‐A and exercise intolerance was independently associated with increased risks of cardiac events. Conclusions: Reduced circulating fetuin‐A levels were associated with exercise intolerance in heart failure patients. Fetuin‐A could emerge as a target implicated in exercise capacity connecting cardiac–hepatic–peripheral interaction and as a valuable biomarker for predicting prognosis when combined with peak oxygen uptake.
- 1 June 2024
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 17 (6) , e011057
Neutrophil Extracellular Traps in Myocardial Tissue Drive Cardiac Dysfunction and Adverse Outcomes in Patients With Heart Failure With Dilated Cardiomyopathy
BACKGROUND: The immune systems and chronic inflammation are implicated in the pathogenesis of dilated cardiomyopathy (DCM) and heart failure. However, the significance of neutrophil extracellular traps (NETs) in heart failure remains to be elucidated. METHODS: We enrolled consecutive 62 patients with heart failure with idiopathic DCM who underwent endomyocardial biopsy. Biopsy specimens were subjected to fluorescent immunostaining to detect NETs, and clinical and outcome data were collected. Ex vivo and in vivo experiments were conducted. RESULTS: The numbers of NETs per myocardial tissue area and the proportion of NETs per neutrophil were significantly higher in patients with DCM compared with non-DCM control subjects without heart failure, and the numbers of NETs were negatively correlated with left ventricular ejection fraction. Patients with DCM with NETs (n=32) showed lower left ventricular ejection fraction and higher BNP (B-type natriuretic peptide) than those without NETs (n=30). In a multivariable Cox proportional hazard model, the presence of NETs was independently associated with an increased risk of adverse cardiac events in patients with DCM. To understand specific underlying mechanisms, extracellular flux analysis in ex vivo revealed that NETs-containing conditioned medium from wild-type neutrophils or purified NET components led to impaired mitochondrial oxygen consumption of cardiomyocytes, while these effects were abolished when PAD4 (peptidyl arginine deiminase 4) in neutrophils was genetically ablated. In a murine model of pressure overload, NETs in myocardial tissue were predominantly detected in the acute phase and persisted throughout the ongoing stress. Four weeks after transverse aortic constriction, left ventricular ejection fraction was reduced in wild-type mice, whereas PAD4-deficient mice displayed preserved left ventricular ejection fraction without inducing NET formation. CONCLUSIONS: NETs in myocardial tissue contribute to cardiac dysfunction and adverse outcomes in patients with heart failure with DCM, potentially through mitochondrial dysfunction of cardiomyocytes.
- 1 June 2024
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 17 (6) , e011057
Neutrophil Extracellular Traps in Myocardial Tissue Drive Cardiac Dysfunction and Adverse Outcomes in Patients With Heart Failure With Dilated Cardiomyopathy
BACKGROUND: The immune systems and chronic inflammation are implicated in the pathogenesis of dilated cardiomyopathy (DCM) and heart failure. However, the significance of neutrophil extracellular traps (NETs) in heart failure remains to be elucidated. METHODS: We enrolled consecutive 62 patients with heart failure with idiopathic DCM who underwent endomyocardial biopsy. Biopsy specimens were subjected to fluorescent immunostaining to detect NETs, and clinical and outcome data were collected. Ex vivo and in vivo experiments were conducted. RESULTS: The numbers of NETs per myocardial tissue area and the proportion of NETs per neutrophil were significantly higher in patients with DCM compared with non-DCM control subjects without heart failure, and the numbers of NETs were negatively correlated with left ventricular ejection fraction. Patients with DCM with NETs (n=32) showed lower left ventricular ejection fraction and higher BNP (B-type natriuretic peptide) than those without NETs (n=30). In a multivariable Cox proportional hazard model, the presence of NETs was independently associated with an increased risk of adverse cardiac events in patients with DCM. To understand specific underlying mechanisms, extracellular flux analysis in ex vivo revealed that NETs-containing conditioned medium from wild-type neutrophils or purified NET components led to impaired mitochondrial oxygen consumption of cardiomyocytes, while these effects were abolished when PAD4 (peptidyl arginine deiminase 4) in neutrophils was genetically ablated. In a murine model of pressure overload, NETs in myocardial tissue were predominantly detected in the acute phase and persisted throughout the ongoing stress. Four weeks after transverse aortic constriction, left ventricular ejection fraction was reduced in wild-type mice, whereas PAD4-deficient mice displayed preserved left ventricular ejection fraction without inducing NET formation. CONCLUSIONS: NETs in myocardial tissue contribute to cardiac dysfunction and adverse outcomes in patients with heart failure with DCM, potentially through mitochondrial dysfunction of cardiomyocytes.
- Open Access
- 1 January 2024
- Published by The Fukushima Society of Medical Science in FUKUSHIMA JOURNAL OF MEDICAL SCIENCE
- Vol. 70 (3) , 111-117
Organ injury and its management in heart failure: Liver, kidney, and thyroid gland dysfunction
Heart failure is hemodynamically characterized as congestion and/or end-organ hypoperfusion, and is associated with increased morbidity and mortality. Underlying pathophysiology, such as neurohormonal activation, exacerbates heart failure and leads to functional deterioration of other organs. We have been conducting clinical research to study the pathophysiology of heart failure and discover prognostic factors. In this review article, we report the results and implications of our clinical research on heart failure.
- 1 January 2024
- Published by The Fukushima Society of Medical Science in FUKUSHIMA JOURNAL OF MEDICAL SCIENCE
- Vol. 70 (3) , 111-117
Open AccessOrgan injury and its management in heart failure: Liver, kidney, and thyroid gland dysfunction
Heart failure is hemodynamically characterized as congestion and/or end-organ hypoperfusion, and is associated with increased morbidity and mortality. Underlying pathophysiology, such as neurohormonal activation, exacerbates heart failure and leads to functional deterioration of other organs. We have been conducting clinical research to study the pathophysiology of heart failure and discover prognostic factors. In this review article, we report the results and implications of our clinical research on heart failure.
- Open Access
- 20 June 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (12) , e029857
Hepatic Venous Stasis Index Reflects Hepatic Congestion and Predicts Adverse Outcomes in Patients With Heart Failure
Background: It has been reported that the hepatic vein waveforms determined by abdominal ultrasonography can assess hepatic congestion in patients with heart failure (HF). However, the parameter that quantifies hepatic vein waveforms has not been established. We suggest the hepatic venous stasis index (HVSI) as the novel indicator to evaluate hepatic congestion quantitatively. To examine the clinical significance of HVSI in patients with HF, we aimed to clarify the associations of HVSI with the parameters of cardiac function and right heart catheterization, as well as that with prognosis, in patients with HF. Methods and Results: We performed abdominal ultrasonography, echocardiography, and right heart catheterization in patients with HF (n=513). The patients were divided into 3 groups based on HVSI as follows: HVSI 0 (HVSI=0, n=253), low HVSI (HVSI 0.01–0.20, n=132), and high HVSI (HVSI>0.20, n=128). We examined the associations of HVSI with parameters of cardiac function and right heart catheterization and followed up for cardiac events defined as cardiac death or worsening HF. There was a significant increase in level of B‐type natriuretic peptide, inferior vena cava diameter, and mean right atrial pressure with increasing HVSI. During the follow‐up period, cardiac events occurred in 87 patients. In the Kaplan–Meier analysis, cardiac event rate increased across increasing HVSI (log‐rank, P =0.002). Conclusions: HVSI assessed by abdominal ultrasonography reflects hepatic congestion and right‐sided HF and is associated with adverse prognosis in patients with HF.
- 20 June 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (12) , e029857
Open AccessHepatic Venous Stasis Index Reflects Hepatic Congestion and Predicts Adverse Outcomes in Patients With Heart Failure
Background: It has been reported that the hepatic vein waveforms determined by abdominal ultrasonography can assess hepatic congestion in patients with heart failure (HF). However, the parameter that quantifies hepatic vein waveforms has not been established. We suggest the hepatic venous stasis index (HVSI) as the novel indicator to evaluate hepatic congestion quantitatively. To examine the clinical significance of HVSI in patients with HF, we aimed to clarify the associations of HVSI with the parameters of cardiac function and right heart catheterization, as well as that with prognosis, in patients with HF. Methods and Results: We performed abdominal ultrasonography, echocardiography, and right heart catheterization in patients with HF (n=513). The patients were divided into 3 groups based on HVSI as follows: HVSI 0 (HVSI=0, n=253), low HVSI (HVSI 0.01–0.20, n=132), and high HVSI (HVSI>0.20, n=128). We examined the associations of HVSI with parameters of cardiac function and right heart catheterization and followed up for cardiac events defined as cardiac death or worsening HF. There was a significant increase in level of B‐type natriuretic peptide, inferior vena cava diameter, and mean right atrial pressure with increasing HVSI. During the follow‐up period, cardiac events occurred in 87 patients. In the Kaplan–Meier analysis, cardiac event rate increased across increasing HVSI (log‐rank, P =0.002). Conclusions: HVSI assessed by abdominal ultrasonography reflects hepatic congestion and right‐sided HF and is associated with adverse prognosis in patients with HF.
- Open Access
- 5 February 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (4) , 1257
Persistent Hypochloremia Is Associated with Adverse Prognosis in Patients Repeatedly Hospitalized for Heart Failure
Background: Hypochloremia reflects neuro-hormonal activation in patients with heart failure (HF). However, the prognostic impact of persistent hypochloremia in those patients remains unclear. Methods: We collected the data of patients who were hospitalized for HF at least twice between 2010 and 2021 (n = 348). Dialysis patients (n = 26) were excluded. The patients were divided into four groups based on the absence/presence of hypochloremia (p < 0.001) and cardiac death (hazard ratio 3.919, p < 0.001). Conclusions: In patients with HF, prolonged hypochloremia over two hospitalizations is associated with an adverse prognosis.
- 5 February 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (4) , 1257
Open AccessPersistent Hypochloremia Is Associated with Adverse Prognosis in Patients Repeatedly Hospitalized for Heart Failure
Background: Hypochloremia reflects neuro-hormonal activation in patients with heart failure (HF). However, the prognostic impact of persistent hypochloremia in those patients remains unclear. Methods: We collected the data of patients who were hospitalized for HF at least twice between 2010 and 2021 (n = 348). Dialysis patients (n = 26) were excluded. The patients were divided into four groups based on the absence/presence of hypochloremia (p < 0.001) and cardiac death (hazard ratio 3.919, p < 0.001). Conclusions: In patients with HF, prolonged hypochloremia over two hospitalizations is associated with an adverse prognosis.
- Open Access
- 7 June 2022
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 11 (11) , e024901
Increases in Hepatokine Selenoprotein P Levels Are Associated With Hepatic Hypoperfusion and Predict Adverse Prognosis in Patients With Heart Failure
Background: Although multiorgan networks are involved in the pathophysiology of heart failure (HF), interactions of the heart and the liver have not been fully understood. Hepatokines, which are synthesized and secreted from the liver, have regulatory functions in peripheral tissues. Here, we aimed to clarify the clinical impact of the hepatokine selenoprotein P in patients with HF. Methods and Results: This is a prospective observational study that enrolled 296 participants consisting of 253 hospitalized patients with HF and 43 control subjects. First, we investigated selenoprotein P levels and found that its levels were significantly higher in patients with HF than in the controls. Next, patients with HF were categorized into 4 groups according to the presence of liver congestion using shear wave elastography and liver hypoperfusion by peak systolic velocity of the celiac artery, which were both assessed by abdominal ultrasonography. Selenoprotein P levels were significantly elevated in patients with HF with liver hypoperfusion compared with those without but were not different between the patients with and without liver congestion. Selenoprotein P levels were negatively correlated with peak systolic velocity of the celiac artery, whereas no correlations were observed between selenoprotein P levels and shear wave elastography of the liver. Kaplan‐Meier analysis demonstrated that patients with HF with higher selenoprotein P levels were significantly associated with increased adverse cardiac outcomes including cardiac deaths and worsening HF. Conclusions: Liver‐derived selenoprotein P correlates with hepatic hypoperfusion and may be a novel target involved in cardiohepatic interactions as well as a useful biomarker for predicting prognosis in patients with HF.
- 7 June 2022
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 11 (11) , e024901
Open AccessIncreases in Hepatokine Selenoprotein P Levels Are Associated With Hepatic Hypoperfusion and Predict Adverse Prognosis in Patients With Heart Failure
Background: Although multiorgan networks are involved in the pathophysiology of heart failure (HF), interactions of the heart and the liver have not been fully understood. Hepatokines, which are synthesized and secreted from the liver, have regulatory functions in peripheral tissues. Here, we aimed to clarify the clinical impact of the hepatokine selenoprotein P in patients with HF. Methods and Results: This is a prospective observational study that enrolled 296 participants consisting of 253 hospitalized patients with HF and 43 control subjects. First, we investigated selenoprotein P levels and found that its levels were significantly higher in patients with HF than in the controls. Next, patients with HF were categorized into 4 groups according to the presence of liver congestion using shear wave elastography and liver hypoperfusion by peak systolic velocity of the celiac artery, which were both assessed by abdominal ultrasonography. Selenoprotein P levels were significantly elevated in patients with HF with liver hypoperfusion compared with those without but were not different between the patients with and without liver congestion. Selenoprotein P levels were negatively correlated with peak systolic velocity of the celiac artery, whereas no correlations were observed between selenoprotein P levels and shear wave elastography of the liver. Kaplan‐Meier analysis demonstrated that patients with HF with higher selenoprotein P levels were significantly associated with increased adverse cardiac outcomes including cardiac deaths and worsening HF. Conclusions: Liver‐derived selenoprotein P correlates with hepatic hypoperfusion and may be a novel target involved in cardiohepatic interactions as well as a useful biomarker for predicting prognosis in patients with HF.
- 1 April 2022
- Published by Baskent University in Experimental and Clinical Transplantation
- Vol. 20 (4) , 362-369
Outcomes of Everolimus Plus Standard-Dose Tacrolimus Immunosuppression in De Novo Kidney Transplant: A Retrospective, Single-Center Study of 225 Transplants
In this study, our aim was to compare the outcomes of everolimus versus mycophenolate mofetil plus standard-dose tacrolimus immunosuppression in patients who received de novo kidney transplant at our center in Fukuoka, Japan. In this retrospective, observational, single-center, inverse probability of treatment weighting analysis study, 225 recipients who underwent kidney transplant at our center between January 2013 and December 2018 were included. The variables considered were recipient age/sex, duration of dialysis, cytomegalovirus mismatch (seronegative recipient and seropositive donor), cause of end-stage renal disease, donor age/sex, and number of HLA mismatches. Our analyses included 85 transplant recipients in the everolimus group and 141 transplant recipients in the mycophenolate mofetil group (n = 226 overall). There were no significant differences between the groups at 1 year for incidence of patient death and allograft loss, biopsy-proven acute rejection, BK virus-associated nephropathy, surgical complications, delayed graft function, and posttransplant diabetes mellitus. Incidence of cytomegalovirus infection and estimated glomerular filtration rate were significantly lower in the everolimus group than in the mycophenolate mofetil group. Posttransplant triglyceride and low-density lipoprotein were higher in the everolimus group than in the mycophenolate mofetil group. Multivariate ordered logistic analysis showed that older donor age and an acute rejection episode, but not induction with everolimus or mean tacrolimus trough concentration throughoutthe firstpostoperative year,were significant risk factors for severity of interstitial fibrosis/tubular atrophy at the 1-year protocol biopsy (P = .004 and P < .001,respectively). Short-term outcomes with everolimus plus standard-dose tacrolimus in recipients of de novo kidney transplant were comparable to those with mycophenolate mofetil plus standard-dose tacrolimus.
- 1 April 2022
- Published by Baskent University in Experimental and Clinical Transplantation
- Vol. 20 (4) , 362-369
Outcomes of Everolimus Plus Standard-Dose Tacrolimus Immunosuppression in De Novo Kidney Transplant: A Retrospective, Single-Center Study of 225 Transplants
In this study, our aim was to compare the outcomes of everolimus versus mycophenolate mofetil plus standard-dose tacrolimus immunosuppression in patients who received de novo kidney transplant at our center in Fukuoka, Japan. In this retrospective, observational, single-center, inverse probability of treatment weighting analysis study, 225 recipients who underwent kidney transplant at our center between January 2013 and December 2018 were included. The variables considered were recipient age/sex, duration of dialysis, cytomegalovirus mismatch (seronegative recipient and seropositive donor), cause of end-stage renal disease, donor age/sex, and number of HLA mismatches. Our analyses included 85 transplant recipients in the everolimus group and 141 transplant recipients in the mycophenolate mofetil group (n = 226 overall). There were no significant differences between the groups at 1 year for incidence of patient death and allograft loss, biopsy-proven acute rejection, BK virus-associated nephropathy, surgical complications, delayed graft function, and posttransplant diabetes mellitus. Incidence of cytomegalovirus infection and estimated glomerular filtration rate were significantly lower in the everolimus group than in the mycophenolate mofetil group. Posttransplant triglyceride and low-density lipoprotein were higher in the everolimus group than in the mycophenolate mofetil group. Multivariate ordered logistic analysis showed that older donor age and an acute rejection episode, but not induction with everolimus or mean tacrolimus trough concentration throughoutthe firstpostoperative year,were significant risk factors for severity of interstitial fibrosis/tubular atrophy at the 1-year protocol biopsy (P = .004 and P < .001,respectively). Short-term outcomes with everolimus plus standard-dose tacrolimus in recipients of de novo kidney transplant were comparable to those with mycophenolate mofetil plus standard-dose tacrolimus.
- 23 February 2022
- Published by Elsevier in Journal of Cardiology
- Vol. 80 (1) , 88-93
B-type natriuretic peptide is associated with the occurrence of bleeding events in heart failure patients with a history of coronary artery disease
- 23 February 2022
- Published by Elsevier in Journal of Cardiology
- Vol. 80 (1) , 88-93
B-type natriuretic peptide is associated with the occurrence of bleeding events in heart failure patients with a history of coronary artery disease